Satralizumab (SA-237) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), acting in neuromyelitis optica spectrum disorder (NMOSD). It is used in studies of neuromyelitis optica.
Purity:
95.00%
CAS Number:
[1535963-91-7]
Target:
Interleukin|||IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted